Group | Pharmacokinetic Parameters | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cmax | AUC0-T | AUC∞ | Tmax | t1/2 | CL/F | ||||||
ng · h/ml | h | h | ml/h | ||||||||
Total radioactivity | |||||||||||
All subjects (n = 10) | 509 (16) | 5305 (24) | 5872 (23) | 1.00 (0.50-2.00) | 8.2 ± 1.69 | 3405 | |||||
Group 1 (n = 6) | 513 (20) | 5087 (26) | 5664 (24) | 1.00 (0.50-2.00) | 8.2 ± 1.59 | 3531 | |||||
Group 2 (n = 4) | 504 (11) | 5649 (22) | 6198 (23) | 1.25 (0.50-2.00) | 8.2 ± 2.09 | 3226 | |||||
Apixaban | |||||||||||
All subjects (n = 10) | 469 (17) | 4050 (25) | 4101 (25) | 1.00 (0.50-2.00) | 12.7 ± 8.55 | 4876 | |||||
Group 1 (n = 6) | 480 (20) | 4055 (30) | 4100 (30) | 1.00 (0.50-2.00) | 12.2 ± 8.48 | 4878 | |||||
Group 2 (n = 4) | 453 (12) | 4041 (20) | 4103 (20) | 1.25 (0.50-2.00) | 13.5 ± 9.91 | 4874 |
CL, clearance; F, bioavailability.